Compare Enveric Biosciences Inc (ENVB) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Kohl's Corporation — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Kohl's Corporation trades at $17.67 (market cap $1.94B). The key difference: Kohl's Corporation is far larger — about 364.7× Enveric Biosciences Inc's market cap, and Kohl's Corporation pays a 2.92% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | KSS | |
|---|---|---|
Market Cap | $5.32M | $1.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $24.71 |
52-Week Low | $1.28 | $9.39 |
Enterprise Value | $408.82K | $8.04B |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Kohl's (KSS) trades at $17.62, up 7.31% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows deep value with a P/E of 7.18 and P/B of 0.48, while recent earnings beats and a 10% jump in juniors sales (Zacks, 2026-06-30) signal early turnaround progress. Cash flow improved to $276M net in 2026 from -$49M in 2025, though revenue has declined from $19.4B in 2022 to $16.2B in 2025.
The outlook hinges on successful execution of Kohl's value-focused strategy and proprietary brand growth to reverse sales declines. Risks include intense retail competition and macroeconomic pressure on consumer spending. Analysts are mixed with a $16.75 consensus target below the current price, suggesting cautious optimism amid restructuring efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
